Toward a unifying hypothesis of metabolic syndrome

Pediatrics

Volumn 129, Issue 3, 2012, Pages 557-570

  Bremer, Andrew A ^a   Mietus Snyder, Michele ^b   Lustig, Robert H ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Dyslipidemia; Hypertension; Insulin resistance; Metabolic syndrome; Pediatrics

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ALCOHOL; APOLIPOPROTEIN B; BRANCHED CHAIN AMINO ACID; CARNITINE PALMITOYLTRANSFERASE I; FORKHEAD TRANSCRIPTION FACTOR; FRUCTOSE 1 PHOSPHATE; GLUCOSE; GLUCOSE 6 PHOSPHATE; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MALONYL COENZYME A; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE C EPSILON; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ALCOHOL CONSUMPTION; BIOGENESIS; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ETHNICITY; GLUCOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PEROXISOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

EID: 84857973646     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2912     Document Type: Review

References (176)

1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994; 17(9):961-969 (Pubitemid 24268605)
2. Wildman RP. Healthy obesity. Curr Opin Clin Nutr Metab Care. 2009;12(4):438-443
3. Conus F, Rabasa-Lhoret R, Péronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab. 2007;32(1):4-12
4. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699-713 (Pubitemid 28201798)
5. Abbasi F, Brown BW, Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40(5):937-943 (Pubitemid 34994988)
6. Despres JP, Lemieux S, Lamarche B, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord. 1995;19(suppl 1):S76-S86
7. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38(1):52-63
8. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1):39-48 (Pubitemid 47016245)
9. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32(6):1068-1075
10. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53 (8):2087-2094 (Pubitemid 38970759)
11. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36): 15430-15435
12. Cali AM, De Oliveira AM, Kim H, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology. 2009;49(6):1896-1903
13. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14 (3):173-194
14. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41 (6):715-722
15. Balkau B, Charles MA; European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med. 1999;16 (5):442-443
16. Kylin E. Studien uber das Hypertonie- Hyperglyka "mie- Hyperurika" miesyndrom. Zentralbl Inn Med. 1923;44:105-127
17. Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15(9): 668-676 (Pubitemid 11208330)
18. Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9(5):452-459
19. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607 (Pubitemid 19004941)
20. Luciano A, Zoppi G. Blood insulin values after the oral glucose tolerance test (OGTT) and the body composition in 30 obese children. Pediatr Med Chir. 1994;16 (5):471-473
21. Biltoft CA, Muir A. The metabolic syndrome in children and adolescents: a clinician's guide. Adolesc Med State Art Rev. 2009;20 (1):109-120
22. Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of body mass index among an international sample of monozygotic twins reared apart. Int J Obes Relat Metab Disord. 1996;20(6): 501-506 (Pubitemid 26174333)
23. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev. 2011;12(11):952-967
24. Monda KL, North KE, Hunt SC, Rao DC, Province MA, Kraja AT. The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2010;10(2):86-108
25. Chen Y, Zhu J, Lum PY, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452(7186): 429-435 (Pubitemid 351450844)
26. Lusis AJ, Attie AD, Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet. 2008;9(11):819-830
27. Sebert S, Sharkey D, Budge H, Symonds ME. The early programming of metabolic health: is epigenetic setting the missing link? Am J Clin Nutr. 2011;94(suppl 6):1953S-1958S
28. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465
29. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107 (17):7892-7897
30. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58(11):2616-2623
31. Pacini G. The hyperbolic equilibrium between insulin sensitivity and secretion. Nutr Metab Cardiovasc Dis. 2006;16(suppl 1):S22-S27
32. Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. Eur J Endocrinol. 2008;159(suppl 1):S67-S74
33. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989;38(12):1512-1527 (Pubitemid 20006675)
34. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822
35. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulinresistant states. Endocr Rev. 1991;12(1): 3-13
36. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002; 51(1):7-18
37. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7(2):95-96 (Pubitemid 351168559)
38. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116 (9):2464-2472 (Pubitemid 44330145)
39. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-340 (Pubitemid 27220877)
40. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109 (9):1125-1131 (Pubitemid 34496588)
41. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996; 37(4):693-707 (Pubitemid 26140808)
42. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993;42(6):833-842 (Pubitemid 23151575)
43. Bergman RN, Kim SP, Hsu IR, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007;120(2 suppl 1):S3-S8 (Pubitemid 46216205)
44. McGarry JD. Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. Biochem Soc Trans. 1995;23 (3):481-485
45. McGarry JD. The mitochondrial carnitine palmitoyltransferase system: its broadening role in fuel homoeostasis and new insights into its molecular features. Biochem Soc Trans. 1995;23 (2):321-324
46. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;244(1):1-14 (Pubitemid 27079689)
47. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36(3):232-240 (Pubitemid 40755136)
48. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2): 171-176 (Pubitemid 30483118)
49. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 suppl 1):S10-S16
50. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733): 2267-2277
51. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000; 106(4):453-458 (Pubitemid 30666377)
52. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365 (9468):1415-1428 (Pubitemid 40523737)
53. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785-789
54. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 1998;14(4):263-283 (Pubitemid 29110250)
55. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473-481 (Pubitemid 30666380)
56. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab. 1998;24(5):409-418 (Pubitemid 28564954)
57. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2276-2283 (Pubitemid 350203940)
58. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008;14(12):1225-1230 (Pubitemid 351997835)
59. Bremer AA, Devaraj S, Afify A, Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(11):E1782- E1788
60. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92(3):1023-1033 (Pubitemid 46465679)
61. Sopasakis VR, Sandqvist M, Gustafson B, et al. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res. 2004;12 (3):454-460 (Pubitemid 41132524)
62. Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res. 1999;31(12): 626-631 (Pubitemid 30056134)
63. Schalch DS, Kipnis DM. Abnormalities in carbohydrate tolerance associated with elevated plasma nonesterified fatty acids. J Clin Invest. 1965;44(12):2010-2020
64. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 1994;93(6):2438-2446 (Pubitemid 24177157)
65. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2): 253-259 (Pubitemid 29053143)
66. Roden M, Krssak M, Stingl H, et al. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes. 1999;48(2): 358-364 (Pubitemid 29061111)
67. Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42(1): 113-116 (Pubitemid 29039748)
68. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104(31):12587-12594 (Pubitemid 47255198)
69. Centers for Disease Control. Trends in intake of energy and macronutrients - United States. Morb Mortal Wkly Rep. 2004;53(4):80-82
70. Muoio DM, Newgard CB. Obesity-related derangements in metabolic regulation. Annu Rev Biochem. 2006;75:367-401 (Pubitemid 44118037)
71. Bonnard C, Durand A, Peyrol S, et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest. 2008;118(2):789-800 (Pubitemid 351206566)
72. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86 (2):285-300 (Pubitemid 47256910)
73. Cave M, Deaciuc I, Mendez C, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18(3):184-195 (Pubitemid 46216810)
74. Chanmugam P, Guthrie JF, Cecilio S, Morton JF, Basiotis PP, Anand R. Did fat intake in the United States really decline between 1989-1991 and 1994-1996? J Am Diet Assoc. 2003;103(7):867-872 (Pubitemid 44348967)
75. York LW, Puthalapattu S, Wu GY. Nonalcoholic fatty liver disease and low-carbohydrate diets. Annu Rev Nutr. 2009; 29:365-379
76. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Tolllike receptor 4. J Biol Chem. 2001;276 (20):16683-16689
77. Willett WC. The great fat debate: total fat and health. J Am Diet Assoc. 2011;111(5): 660-662
78. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757 (Pubitemid 35364932)
79. Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol. 2009;15(15):1809-1815
80. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T. Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr. 2005;135(1):9-13 (Pubitemid 40094313)
81. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009;94(10):3842-3848
82. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771(8):972-982
83. Rasooly R, Kelley DS, Greg J, Mackey BE. Dietary trans 10, cis 12-conjugated linoleic acid reduces the expression of fatty acid oxidation and drug detoxification enzymes in mouse liver. Br J Nutr. 2007;97(1):58-66 (Pubitemid 46662059)
84. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G987-G995
85. Dorfman SE, Laurent D, Gounarides JS, et al. Metabolic implications of dietary trans-fatty acids. Obesity (Silver Spring). 2009;17(6):1200-1207
86. Layman DK, Walker DA. Potential importance of leucine in treatment of obesity and the metabolic syndrome. J Nutr. 2006; 136(suppl 1):319S-323S
87. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4): 311-326
88. Higuchi N, Kato M, Miyazaki M, et al. Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucosesensing apparatus in the liver. J Cell Biochem. 2011;112(1):30-38
89. Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. J Clin Invest. 1998;101(7):1519- 1529 (Pubitemid 28166850)
90. Baum JI, O'Connor JC, Seyler JE, Anthony TG, Freund GG, Layman DK. Leucine reduces the duration of insulin-induced PI 3-kinase activity in rat skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288 (1):E86-E91 (Pubitemid 40023794)
91. Chotechuang N, Azzout-Marniche D, Bos C, et al. mTOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat. Am J Physiol Endocrinol Metab. 2009;297(6):E1313- E1323
92. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006;3(6):393-402 (Pubitemid 43811780)
93. Eaton S. Control of mitochondrial betaoxidation flux. Prog Lipid Res. 2002;41(3): 197-239
94. Harper AE, Miller RH, Block KP. Branchedchain amino acid metabolism. Annu Rev Nutr. 1984;4:409-454
95. Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002;51(3):599-605 (Pubitemid 34760165)
96. Krebs M, Brehm A, Krssak M, et al. Direct and indirect effects of amino acids on hepatic glucose metabolism in humans. Diabetologia. 2003;46(7):917-925 (Pubitemid 36961314)
97. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab. 2007;293 (6):E1552-E1563 (Pubitemid 350255104)
98. Herman MA, She P, Peroni OD, Lynch CJ, Kahn BB. Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. J Biol Chem. 2010; 285(15):11348-11356
99. Floyd JC, Jr, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest. 1966;45(9): 1487-1502
100. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4): 448-453
101. Tai ES, Tan ML, Stevens RD, et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010;53(4):757-767
102. Facchini F, Chen YD, Reaven GM. Light-tomoderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care. 1994;17(2):115-119 (Pubitemid 24035305)
103. Di Castelnuovo A, Costanzo S, di Giuseppe R, de Gaetano G, Iacoviello L. Alcohol consumption and cardiovascular risk: mechanisms of action and epidemiologic perspectives. Future Cardiol. 2009;5(5): 467-477
104. Athyros VG, Liberopoulos EN, Mikhailidis DP, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007;58(6):689-697
105. Sakurai Y, Umeda T, Shinchi K, et al. Relation of total and beverage-specific alcohol intake to body mass index and waist-to-hip ratio: a study of self-defense officials in Japan. Eur J Epidemiol. 1997;13(8):893-898 (Pubitemid 28046718)
106. Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome. Am J Clin Nutr. 2008;87(5):1455-1463 (Pubitemid 351679790)
107. Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc. 2010;110(9):1307-1321
108. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology. 2006;43(2 suppl 1):S63-S74
109. García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie. 2008;90(3): 460-466 (Pubitemid 351232118)
110. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell. 1993;77(1):67-76 (Pubitemid 23135586)
111. Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab. 2008;295(1):E10-E16
112. Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis. Ann Intern Med. 1991;114(11):967-976
113. Suter PM, Schutz Y. The effect of exercise, alcohol or both combined on health and physical performance. Int J Obes (Lond). 2008;32(suppl 6):S48-S52
114. Schneider J, Tesdorfpf M, Kaffarnik H, Hausmann L, Zöfel P, Zilliken F. Alteration of plasma lipids and intermediates of lipid metabolism in healthy fasting volunteers by ethanol and fructose. Res Exp Med (Berl). 1976;167(2):159-170
115. Lee YJ, Aroor AR, Shukla SD. Temporal activation of p42/44 mitogen-activated protein kinase and c-Jun N-terminal kinase by acetaldehyde in rat hepatocytes and its loss after chronic ethanol exposure. J Pharmacol Exp Ther. 2002;301(3): 908-914 (Pubitemid 34595079)
116. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol. 2004; 34(1):39-43
117. Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferatoractivated receptor alpha. Alcohol. 2004;34 (1):35-38
118. Guzmán M, Castro J. Alterations in the regulatory properties of hepatic fatty acid oxidation and carnitine palmitoyltransferase I activity after ethanol feeding and withdrawal. Alcohol Clin Exp Res. 1990;14(3):472-477 (Pubitemid 20195132)
119. Yokoyama H, Hiroshi H, Ohgo H, Hibi T, Saito I. Effects of excessive ethanol consumption on the diagnosis of the metabolic syndrome using its clinical diagnostic criteria. Intern Med. 2007;46(17):1345-1352 (Pubitemid 47455756)
120. Onishi Y, Honda M, Ogihara T, et al. Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation. Biochem Biophys Res Commun. 2003;303(3):788-794 (Pubitemid 36384924)
121. Marriott BP, Olsho L, Hadden L, Connor P. Intake of added sugars and selected nutrients in the United States, National Health and Nutrition Examination Survey (NHANES) 2003-2006. Crit Rev Food Sci Nutr. 2010;50(3):228-258
122. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008;10(7):160
123. Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr. 2008;88(6):1733S-1737S
124. Abraha A, Humphreys SM, Clark ML, Matthews DR, Frayn KN. Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. Br J Nutr. 1998; 80(2):169-175 (Pubitemid 28451428)
125. Cohen JC, Schall R. Reassessing the effects of simple carbohydrates on the serum triglyceride responses to fat meals. Am J Clin Nutr. 1988;48(4):1031-1034
126. Teff KL, Elliott SS, Tschöp M, et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab. 2004;89 (6):2963-2972 (Pubitemid 38766393)
127. Stanhope KL, Griffen SC, Bair BR, Swarbrick MM, Keim NL, Havel PJ. Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr. 2008; 87(5):1194-1203 (Pubitemid 351679758)
128. Swarbrick MM, Stanhope KL, Elliott SS, et al. Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein- B concentrations in overweight and obese women. Br J Nutr. 2008;100(5):947-952
129. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev. 2005;63(5):133-157
130. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79(4):537-543
131. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr. 2006;84(2):274-288 (Pubitemid 44699135)
132. Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 2008;19(1):16-24
133. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322-1334
134. Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. Caloric sweetener consumption and dyslipidemia among US adults. JAMA. 2010;303(15): 1490-1497
135. Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation. 2010; 121(11):1356-1364
136. Bremer AA, Auinger P, Byrd RS. Relationship between insulin resistance-associated metabolic parameters and anthropometric measurements with sugar-sweetened beverage intake and physical activity levels in US adolescents: findings from the 1999-2004 National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2009;163(4):328-335
137. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452-1455
138. Collison KS, Saleh SM, Bakheet RH, et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring). 2009;17(11):2003-2013
139. Lê KA, Ith M, Kreis R, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009;89 (6):1760-1765
140. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7(5):251-264
141. Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90(1):23-46
142. Bjorkman O, Crump M, Phillips RW. Intestinal metabolism of orally administered glucose and fructose in Yucatan miniature swine. J Nutr. 1984;114(8):1413-1420 (Pubitemid 14052488)
143. Nagai Y, Yonemitsu S, Erion DM, et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab. 2009;9(3):252-264
144. Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005; 54(7):1907-1913 (Pubitemid 40911251)
145. Matsuzaka T, Shimano H, Yahagi N, et al. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocintreated mice. Diabetes. 2004;53(3):560-569 (Pubitemid 38270623)
146. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, Kashiwagi A. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Am J Physiol Endocrinol Metab. 2002;282(5): E1180-E1190 (Pubitemid 34654734)
147. Wei Y, Wang D, Pagliassotti MJ. Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J Nutr. 2005;135(7): 1642-1646 (Pubitemid 40980712)
148. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Fructose-mediated stress signaling in the liver: implications for hepatic insulin resistance. J Nutr Biochem. 2007; 18(1):1-9 (Pubitemid 44827722)
149. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-336 (Pubitemid 35398190)
150. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006; 55(suppl 2):S9-S15
151. Teff KL, Grudziak J, Townsend RR, et al. Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab. 2009;94(5):1562-1569
152. Civitarese AE, Ravussin E. Mitochondrial energetics and insulin resistance. Endocrinology. 2008;149(3):950-954
153. Parola M, Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal. 2011;15(2):461-483
154. Subasinghe W, Syed I, Kowluru A. Phagocyte-like NADPH oxidase promotes cytokineinduced mitochondrial dysfunction in pancreatic b-cells: evidence for regulation by Rac1. Am J Physiol Regul Integr Comp Physiol. 2011;300(1):R12-R20
155. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003; 552(pt 2):335-344 (Pubitemid 37321833)
156. Fan X, Hussien R, Brooks GA. H2O2-induced mitochondrial fragmentation in C2C12 myocytes. Free Radic Biol Med. 2010;49 (11):1646-1654
157. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9(12):2277-2293 (Pubitemid 350059010)
158. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008; 54(6):945-955 (Pubitemid 351793400)
159. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science. 1981;213 (4504):222-224 (Pubitemid 11060569)
160. Thoms S, Grønborg S, Gärtner J. Organelle interplay in peroxisomal disorders. Trends Mol Med. 2009;15(7):293-302
161. Dirkx R, Vanhorebeek I, Martens K, et al. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities. Hepatology. 2005;41(4): 868-878 (Pubitemid 40462950)
162. Schrader M, Fahimi HD. Peroxisomes and oxidative stress. Biochim Biophys Acta. 2006;1763(12):1755-1766 (Pubitemid 44880480)
163. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ. Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact. 2009;178(1-3):332-339
164. Pickens MK, Yan JS, Ng RK, et al. Dietary sucrose is essential to the development of liver injury in the methionine-cholinedeficient model of steatohepatitis. J Lipid Res. 2009;50(10):2072-2082
165. Kapoor A, Sanyal AJ. Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis. 2009;13(4):581-590
166. Merksamer PI, Trusina A, Papa FR. Realtime redox measurements during endoplasmic reticulum stress reveal interlinked protein folding functions. Cell. 2008;135(5): 933-947
167. Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ERderived oxidative stress and cell death. Mol Cell. 2004;15(5):767-776 (Pubitemid 39194906)
168. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal. 2009;11(10):2409-2427
169. Mollica MP, Lionetti L, Putti R, Cavaliere G, Gaita M, Barletta A. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr Metab Cardiovasc Dis. 2011;21(3): 222-230
170. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res. 2010;107 (5):579-591
171. Yki-Järvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care. 2010;13(6):709-714
172. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med. 2000;342(19):1392-1398 (Pubitemid 30262396)
173. Brynes AE, Mark Edwards C, Ghatei MA, et al. A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. Br J Nutr. 2003;89(2):207-218 (Pubitemid 36215859)
174. Lira VA, Benton CR, Yan Z, Bonen A. PGC- 1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;299(2):E145-E161
175. Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci. 2008;1147:37-52
176. Hannukainen JC, Borra R, Linderborg K, et al. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. J Hepatol. 2011;54(3):545-552